(AA) due to kick things off April 10, followed shortly after by the big banks with JPMorgan (JPM) opening its books on April 13. Ed Yardeni, chief investment strategist at Yardeni Research, took a forward-looking view of the markets on Wednesday, moving up his year-end forecast of 1450-1550 for the S&P 500 to the end of summer. The index closed Wednesday at 1405.54. "If the economy falls off a fiscal cliff in 2013, so will earnings," he wrote in emailed commentary. "The question is when might the stock market start to discount such a scenario? Investors are likely to do so well ahead of industry analysts, who probably won't lower their earnings estimates until company managements tell them that they are going over a cliff. In my opinion, the fiscal cliff scenario won't be an issue for the market until right after the summer, when investors are likely to focus more of their attention on the political races." After the summer, Yardeni said: "
ll bets are off given the uncertainty about fiscal policy. I have to believe that the lame ducks in Congress will pass temporary measures that postpone the fiscal cliff scenario until the new Congress has a chance to address the mess early in 2013."
As for Thursday's scheduled news,
(BBY) is the big name reporting its quarterly results before the opening bell, and the average estimate of analysts polled by
Thomson Reuters is for a profit of $2.16 a share on revenue of $17.2 billion in the February-ended period.
Best Buy shares have bounced more than 15% so far in 2012, but are still off nearly 8% in the past year, pushing the forward price-to-earnings multiple down to 7.2X. The Minneapolis-based consumer electronics retailer reaffirmed its outlook for adjusted earnings of $3.35 to $3.65 a share in fiscal 2012 on Jan. 6 but said revenue of $8.4 billion for December was "slightly lower" than expectations because customer traffic was slow until the last week before Christmas.
- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer